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Abstract: Aggregatibacter actinomycetemcomitans has been described as a member of the 
indigenous oral microbiota of humans, and is involved in the pathology of periodontitis 
and various non-oral infections. This bacterium selectively kills human leukocytes through 
expression of leukotoxin, a large pore-forming protein that belongs to the Repeat in Toxin 
(RTX) family. The specificity of the toxin is related to its prerequisite for a specific target 
cell receptor, LFA-1, which is solely expressed on leukocytes. The leukotoxin causes death 
of different leukocyte populations in a variety of ways. It activates a rapid release of 
lysosomal enzymes and MMPs from neutrophils and causes apoptosis in lymphocytes. In 
the monocytes/macrophages, the toxin activates caspase-1, a cysteine proteinase, which 
causes a proinflammatory response by the activation and secretion of IL-1β and IL-18. A 
specific clone (JP2) of A. actinomycetemcomitans with enhanced leukotoxin expression 
significantly correlates to disease onset in infected individuals. Taken together, the 
mechanisms by which this toxin kills leukocytes are closely related to the pathogenic 
mechanisms of inflammatory disorders, such as periodontitis. Therapeutic strategies 
targeting the cellular and molecular inflammatory host response in periodontal diseases 
might be a future treatment alternative. 
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1. Aggregatibacter actinomycetemcomitans 
Aggregatibacter actinomycetemcomitans is a gram-negative bacterium that is present in the oral 
cavity of a large proportion of the human population [1]. The prevalence of this bacterium shows great 
variation depending on the geographic origin, age and life style of the examined population [2,3]. 
A. actinomycetemcomitans is part of the normal flora in many healthy individuals but is also a major 
etiologic agent in some aggressive forms of periodontitis [4]. Periodontitis is a chronic infectious 
inflammatory disease characterized by the destruction of tooth-supporting structures [5]. The 
contribution of bacteria to the disease progression is poorly understood, probably due to  the 
multifactorial background of this disease. The number and composition of bacteria in the oral biofilm, 
as well as life style and genetic predisposition, are factors that determine the outcome of the disease 
activity [6,7]. The genetic diversity among different isolates of A. actinomycetemcomitans is great and 
its ability to express and release virulence factors varies [1]. The different adhesins and fimbria 
expressed by this bacterium have been shown to be important factors that promote colonization at the 
various ecological niches of the human oral cavity [4]. A. actinomyctemcomitans  expresses two 
exotoxins, a cytolethal distending toxin (Cdt) and a leukotoxin. Cdt’s are expressed by a number of 
gram-negative bacteria and cause death of the host cells by blocking their proliferation [8]. The 
leukotoxin selectively affects human cells of hematopoetic origin by binding to the lymphocyte 
function associated receptor 1 (LFA-1) and disrupting membrane integrity [9]. Leukotoxin belongs to 
the Repeat in Toxin family (RTX) and shares genome organization and molecular structures with RTX 
proteins produced by a number of other gram-negative bacteria [10]. The expression of leukotoxin and 
Cdt varies among different A. actinomycetemcomitans isolates and high leukotoxin expression has 
been shown to correlate with disease while the role of Cdt is still less  clear [1]. The interaction 
between leukotoxin and host cells will be the focus of the present paper. 
2. Leukotoxin Production 
The A. actinomycetemcomitans leukotoxin operon consists of four coding genes designated ltxC, ltxA, 
ltxB and ltxD and an upstream promoter [11]. ltxA encodes the structure of the toxin, ltxC for 
components required for posttranslational acylation of the toxin and ltxB and D for transport of 
the toxin to the bacterial outer membrane. The leukotoxin promoter is located upstream of the ltxC  
gene (Figure 1).  
Figure 1. Organization of the A. actinomycetemcomitamns leukotoxin operon. 
 
There is great variation in leukotoxin expression in vitro, although all A. actinomycetemcomitans 
strains harbor a complete leukotoxin operon [1]. Zambon and co-workers [12] showed that 
A. actionomycetemcomitans  isolated from periodontally diseased subjects exhibited significantly 
enhanced leukotoxicity compared with isolates from periodontally healthy subjects. Interestingly, 
certain clones  of the bacterium with enhanced leukotoxin expression have been shown to have a 
modified promoter in the leukotoxin operon [13,14]. The cellular and molecular mechanisms in which Toxins 2011, 3             
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a modified leukotoxin promoter enhances the expression of leukotoxin are not known. The most well 
known phenomenon is the highly leukotoxic JP2 clonal strains of A. actinomycetemcomitans 
characterized by a 530 bp deletion in the promoter of the leukotoxin operon [3]. Hypertonic NaCl 
extracts of bacteria from this clone separated by SDS-PAGE and stained with Coomassie, revealed a 
protein pattern that was dominated by a 116 kDa band shown to be the leukotoxin [15] (Figure 2).  
Figure  2.  Surface extract of bacteria from a highly leukotoxic  (JP2) strain of 
A. actinomycetemcomitans  (HK1619) separated by SDS-PAGE and stained with 
Coomassie blue. The 116 kD LtxA is released from the bacterial surface in the presence of 
≥300 mM NaCl and dominates the protein profile in these extracts [15]. 
116 kDa
(LtxA)
 
Presence of the JP2 clone is highly associated to aggressive forms of periodontitis and has been 
shown to correlate with disease onset of adolescents in Morocco [16]. This  highly leukotoxic   
clone (JP2) has recently been reported to also colonize subjects of North-European origin confirmed 
by genotyping [17]. Clonal diversity analyses of JP2-like isolates have indicated that all strains of this 
clone have a common ancestor from Northern Africa [18]. The high accumulation of this clone in 
subjects of African origin has indicated a possible host tropism, but could also be a result of the strict 
vertical transmission pattern of this bacterium [3]. The expression of leukotoxin is also regulated by 
environmental factors, such as growth conditions and substrates [11]. The expression of leukotoxin by 
various strains of A. actinomycetemcomitans at the infected site of the host is still not known. 
3. Leukotoxin Secretion 
The expressed A. actinomyctemcomitans leukotoxin is transported to the bacterial outer membrane 
by a type I secretion system [11,19]. This secretion mechanism is shared with other proteins of the 
RTX family [10]. Three proteins of A. actinmycetemcomitans, LtxB, LtxD and TdeA, are reported to 
be required for export of the toxin to the bacterial outer membrane (Figure 3) [20]. In addition, an 
inner membrane protein (MorC) that affects the outer membrane structure has been shown to be 
necessary for efficient export of the toxin [21]. The localization of the toxin was found to be on the 
outside of the membrane and in membrane associated vesicles [22,23]. Whether the expressed and 
exported leukotoxin remains  associated  with  the bacterial outer membrane or is secreted to the 
environment is a topic of controversy and the mechanisms that keep the toxin associated with the Toxins 2011, 3             
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membrane are still not fully understood. A hydrophobic domain of the molecule has been suggested to 
mediate association with the cell membrane [24]. Ohta and co-workers [25,26] showed that leukotoxin 
could be released from the bacterial membrane by DNase or RNase  treatment, which indicates 
involvement also of electrostatic forces between the negative charged nucleic acid and the positive 
charged leukotoxin. This was further confirmed by the observation that leukotoxin is released from the 
bacterial membrane and vesicles in hypertonic NaCl solutions [15] (Figure 2). In addition, presence of 
serum proteins also mediates release of the toxin from the bacterial outer membrane, which indicates 
involvement of competitive mechanisms [27]. Different culture conditions have been shown to 
determine the distribution of the expressed toxin between the bacterial outer membrane and the culture 
supernatant [28,11]. Whether leukotoxin is associated with the bacterial membrane or released to the 
environment at the site of infection is still not known. However, the serum mediated release of the 
toxin [27], as well as its highly systemic immunogenic response [29], indicates a release of the toxin 
from bacteria growing in an oral biofilm in vivo. Among the different proteins of the RTX family, 
A. actinomycetemcomitans leukotoxin differs from the other toxins by its high isoelectric point, as well 
as the membrane association of the expressed protein [10]. This property of LtxA further supports the 
importance of electrostatic forces for its association to the bacterial outer membrane. 
Figure 3. Schematic illustration of the type I secretion system required for export of the 
expressed A. actinomycetemcomitamns leukotoxin to the bacterial outer membrane (OM). 
IM = Inner membrane; TdeA = a TolC like protein (from Kachlany [20] with permission). 
 
The secreted leukotoxin has been shown to be easily inactivated by environmental proteases and 
superoxide radicals [30–32]. This degradation of the toxin molecule can be inhibited by the presence 
of superoxide dismutase (SOD) produced by A. actinomycetemcomitans and the naturally occurring 
protease inhibitors of human serum [31–33]. In 1981, McArthur and co-workers showed that the 
activity of leukotoxin in interaction with polymorphonuclear leukocytes (PMNs) was enhanced in the 
presence of human serum [34]. This phenomenon could later be explained by the protective effect of 
the serum protease inhibitors on leukotoxin degradation caused by lysosomal enzymes released by the 
affected PMNs [31]. Toxins 2011, 3             
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4. Molecular Structure of the Leukotoxin 
The focus in this section, as well as throughout the whole manuscript, is directed to the 
A. actinomycetemcomitans leukotoxin (LtxA) if not otherwise indicated [11]. However, many of the 
structural and functional properties of LtxA are shared with the other proteins of the RTX family, 
therefore motivating a brief overview about this toxin family [10]. The RTX proteins are a highly 
diverse steadily growing family of toxins secreted from a number of gram negative bacterial species 
and with a wide range different biological activities [10]. RTX proteins fall into two categories: the 
hemolysins, which affect a variety of cell types, and the leukotoxins, which are cell-type-  and  
species-specific [9]. RTX hemolysins appear to rely on electrostatic interactions to anchor the toxin on 
the cell membranes and the repeat region does not appear necessary for cell lysis [9]. In addition, a 
quite different and recently discovered division of the RTX family is the MRTX, which is a group of 
very large toxins that differ from all previously known RTX proteins by the molecular structure and 
gene cluster organization [10]. LtxA expressed by A. actinomyctemcomitans is a large pore-forming 
protein that consists of 1055 amino acids encoded by the ltxA gene in the leukotoxin operon [24,35]. 
The molecule can be divided into four regions based upon analysis of the amino acid sequence: the  
N-terminal region, the central region, the repeat region and the C-terminal region (Figure 4) [36]. 
These four regions in the molecule structure are shared among many of the bacterial proteins in the 
RTX family [10,37].  
Figure 4.  Schematic illustration of the molecular structure of the  interaction between 
leukotoxin and the target cell membrane (from Lally [9] with permission). 
 
The N-terminal region, residues 1–408, of LtxA exhibits alternating hydrophobic and hydrophilic 
clusters and the pore-forming region have been suggested to be mediated by the hydrophobic clusters 
located between residues 175–400 [9,36,37]. The central region  of the RTX proteins at  residues  
409–729 contains large hydrophilic domains and the two acylation sites of LtxA is located at lysine562 
and lysine687 [38]. The fatty acids at these positions have been shown necessary for the activity of the 
toxin and are suggested to contribute to the anchorage at the target cell membrane [38,39]. The repeat 
region of the RTX proteins consists of tandem repeats of a cassette with nine amino acids located 
between residues 730–900 and 14 such repeats have been identified in this region of LtxA [36,40]. The 
target cell receptor LFA-1 binds to the repeat region and this interaction has been shown to be 
responsible for the host cell specificity of LtxA [40,41]. In addition, the glycine rich repeats in this 
region have strong capacity to bind Ca
2+ and presence of these cations mediates increased binding of 
the toxin to LtxA-sensitive LFA-1 expressing cells [42]. Finally, residues 901–1055 at the C-terminal 
end of the RTX proteins have been shown to be needed for export of the toxin to the bacterial outer Toxins 2011, 3             
 
247 
membrane by interactions with secretory proteins [37]. This region of LtxA contains 20 extra basic 
amino acid residues in comparison with other RTX-proteins and is the reason for its high isoelectric 
point (9.7) [35]. Even though the four regions of LtxA described above are shared among the various 
toxins in the diverse family of pore forming RTX proteins, their amino acid sequence homology is 
limited to about 40–50%, with the highest homology between their repeat regions and the lowest 
between their C-terminal regions [35,37]. A partial denaturation of the LtxA molecule has been reported 
to enhance its leukotoxicity, which indicates that conformational changes interact with the activity of the  
toxin [43].  Some minor differences have been identified on the ltxA  genes between different   
A. actinomycetemcomitans isolates but whether these differences interfere with leukotoxicity is not 
known [24,35,44]. The crystalline structure of LtxA has not yet been solved, which limits the available 
information about the molecular structures of the protein. 
5. Interaction of LtxA with the Target Cell Membrane 
LtxA  expressed by A. actinomycetemcomitans  exhibits a unique specificity against cells of 
hematopoetic origin from humans and some other primates [41]. This restricted host
 cell specificity 
suggests that the species-specific effect
 of LtxA is mediated through a unique receptor on
 the target 
cells and a precise region in the toxin that
 recognizes and interacts with the receptor [45,46]. The 
principal feature
 of this species recognition region of LtxA is that
 
LtxA has been shown  to bind surfaces of toxin-sensitive LFA-1 expressing cells, as well as   
toxin-resistant cells without LFA-1 expression [42]. It has been suggested that the role of LFA-1 in 
LtxA mediated cell lysis is to help the protein to have a correct orientation on the target cell   
membrane (Figure 4) [9]. Further, the two fatty acids strengthen the anchorage of the toxin when 
inserted in the target cell membrane and the hydrophobic domain forms small pores in the membrane. 
It has been  stated that low concentrations  of the toxins might induce apoptosis through loss of 
membrane integrity caused by the small pores and that higher concentrations  of the toxin allows 
oligomerizerization of LtxA-LFA-1 complexes on the target cell membrane, mediating a rapid and 
complete membrane collapse [9]. In addition, LtxA has been shown to require lipid rafts for target 
cytotoxicity, which also indicates the importance of a high mobility on the target cell membrane [47]. 
it contains a series of 14 tandemly 
repeated amino acid sequences in the repeat region of the toxin [36,40]. 
The domain of LtxA that  recognizes  the target cell receptor has been shown  to  be  residues  
688–941,  examined by epitope mapping with monoclonal antibodies [40]. The LFA-1 molecule 
identified as the LtxA target cell receptor is a heterodimer consisting of the αL (CD11a) and β2 
(CD18) subunits. The residues 1–128 on human CD11a have been shown to be important for the 
human specificity of LtxA-induced cell lysis [46]. In addition, the extracellular region of human CD18 
(residues 500–600) has been shown to be critical for conferring susceptibility to LtxA-induced cell 
lysis [45]. The most important ligand of LFA-1 is the intercellular adhesion molecule 1 (ICAM-1), but 
this interaction does not coincide with the residues identified for the LtxA binding [45,46,48]. This 
finding indicates that the intracellular signaling mediated by the LFA-1 ligand binding is not activated 
by the LtxA binding. Three different affinity states (low, intermediate, high) of LFA-1 that interfere 
with ligand binding have been described [49]. It is not known if these different affinity states of the 
LtxA receptor interfere with the interactions between LtxA and its target cells.  Toxins 2011, 3             
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6. Virulence Mechanisms of the Leukotoxin (LtxA) 
The ability of A. actinomycetemcomitans extracts to cause death of leukocytes was first shown more 
than 30 years ago [50,51]. A protein named leukotoxin was identified as the responsible molecule for 
this leukotoxic effect that was restricted to human PMNs and monocytes [50–52]. It was later shown 
that leukotoxin can also affect human lymphocytes and erythrocytes from human and animal origin, 
however, at higher concentrations of the toxin than which lyses PMNs and monocytes [53,54]. 
6.1. Polymorphonuclear Leukocytes 
PMNs are the first defense cells to be recruited in the acute phase of an inflammation, as in a 
periodontal infection [55]. These defense cells are often found in  high numbers in the infected 
periodontal pocket, attracted from the peripheral circulation through chemotaxis towards a gradient of 
molecules released from the oral biofilm, as well as activated host cells. Although PMNs are crucial 
for phagocytizing and killing the bacteria, they have also been shown to release substances that 
mediate tissue destruction in aggressive forms of periodontitis [56]. PMNs in the periodontium have 
been described as a “double-edged sword”, capable of producing periodontal disease as well as 
protecting against such disease [57]. LtxA,  as well as leukotoxic bacteria,  have been shown to 
efficiently cause death of human PMNs,  and consequently LtxA is  assumed to protect 
A. actinomycetemcomitans  against phagocytic killing [1]. The protection depends on the LtxA 
concentration of the bacterial population [58]. In a mixture of low-leukotoxic bacteria, human serum 
and PMNs that is agitated at 37  °C under anaerobic conditions, the bacteria are efficiently 
phagocytized and killed at a ratio of 25 bacteria/PMN [58]. In contrast, in the presence of highly 
leukotoxic (JP2-clone) bacteria under the same physiological conditions, the PMNs fail to phagocytize 
and kill the bacteria. Transmission electron microscopy pictures of the exposed PMNs showed a 
peripheral translocation of the granules in cells exposed to the highly leukotoxic bacteria (Figure 5). 
Further analyses of PMNs exposed  to leukotoxin showed an extracellular release of proteolytic 
enzymes from both primary and secondary granules [30]. Moreover, the interaction between LtxA and 
PMNs mediates activation and release of matrix metalloproteinase 8 [59,60]. Taken together, these 
findings indicate that beyond causing death of the PMNs, LtxA also induces activation and release of 
proteolytic enzymes from these cells, which might contribute to the disease progression. 
Whether LtxA can exist as a biologically active protein in the infected periodontal pocket has not 
yet been examined. The presence of serum proteins and the relatively high pH (≈8) in the pocket 
indicates that LtxA is released from the bacterial surface in this ecological niche [27,35]. The released 
toxin makes it to an easy target for inactivation by several of the components present in the periodontal 
pocket, such as superoxide  radicals and proteinases released from the host defense cells or the 
colonizers of the oral subgingival biofilm [15,27,32]. In addition, it has been shown that systemic 
antibodies with specific reactivity against LtxA neutralize leukotoxic activity, but if these antibodies 
are functional in the complex ecological niche of an infected periodontal pocket is not known [29]. 
There are also molecules in the periodontal pocket that can protect LtxA from inactivation, such as the 
host serum proteinase inhibitors and bacterial SOD expressed by A. actinomycetemcomitans [31,32]. 
The great variation over time in the balance between these factors probably affects the activity of LtxA Toxins 2011, 3             
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at the infected site and the burst periods observed in the pathogenesis of periodontitis might depend on 
such a phenomenon. 
Figure 5.  Polymorphonuclear leukocytes (PMNs)  were  exposed to live   
A. actinomycetemcomitans for 10 min in a ratio of 25 bacteria/PMN, in the presence of 
10% human non-immune sera at 37 °C under anaerobic conditions with gentle agitation. 
The low leukotoxic bacteria were phogocytized and killed by the PMN (left), while the 
highly leukotoxic bacteria (JP2) resisted  PMN phagocytosis and caused  extracellular 
release of lysosomal components (right) [58]. 
Minimally-leukotoxic Highly-leukotoxic  
Impaired PMN function is closely associated with periodontitis and functional PMNs seems to  
be of certain importance when A. actinomycetemcomitans  is present in the oral  subgingival  
biofilm [33,55,59–61]. For instance, PMNs of subjects with Kostmann’s syndrome are immature and 
express truncated LL37, a cathelicidin with antibacterial effect against A. actinomycetemcomitans [61]. 
Furthermore, subjects with Papillon-Lefèvre syndrome  have  impaired  PMN serine proteases 
maturation, which causes an enhanced LtxA sensitivity due  to  decreased capacity to degrade 
extracellular LtxA by the released lysosomal PMN enzymes [33]. 
6.2. Lymphocytes 
The lymphocytes were initially described as LtxA resistant cells [50,51]. The first observation of 
LtxA susceptible cells of lymphocytic origin was by Simpson and co-workers [62] who  showed  
that several lymphoid cell lines were killed in the presence of LtxA. In addition, LtxA was shown to 
suppress  the  function of peripheral blood lymphocytes [63,64]. A  few years later,  Mangan and   
co-workers [53] showed that T-cells isolated from human peripheral blood were affected by LtxA. 
This LtxA-induced T-cell death was a slow process compared to that which lyses human cells of 
myeloid origin and the cell death was shown to be induced through apoptosis [53]. It has also been 
shown that the human natural killer (NK) cells are affected in a similar way by LtxA as the T-cells, 
while the effects of LtxA  on  human B-cells or plasma-cells not have been specifically   
addressed [63,64]. Human lymphocytes show a great heterogeneity in regard to LtxA sensitivity and a 
subgroup of these cells has been shown to be lysed at approximately the same concentrations as human Toxins 2011, 3             
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PMNs [65]. The lymphocytes with different LtxA sensitivity were not further characterized in this 
study but analyses of CD11a expression on there cell membrane showed a heterogenic distribution 
pattern in this cell population. The reason for the variation in LtxA sensitivity between PMNs and 
lymphocytes is not known. The suggested oligomerization of LtxA-LFA-1 complex and the need of 
lipid rafts on the target cell membrane may indicate that the composition of membrane molecules on 
the target cells determine the source of LtxA-induced death mechanisms [9,49]. It has been shown that 
low concentrations of LtxA cause apoptosis, and in higher concentrations necrosis, in cultures of a 
human carcinoma cell line of myeloid origin (HL-60) [66]. 
Cells of lymphoid origin are rare in the infected periodontal pocket but reside in high numbers in 
the surrounding tissues as well as in the lymph glands [67]. It has been known for >30 years that the 
onset of periodontitis involves a switch from a T cell lesion to one involving large numbers of B-cells 
and plasma cells. A shift occurs in the balance between the so-called Th1 and Th2 subsets of T-cells, 
with Th2 cells associated to chronic periodontitis [68]. More recently, T regulatory (Treg) and Th17 
cells have been detected in periodontal tissues, indicating that these cells also are of importance in the 
host response and pathogenesis of periodontal disease [69]. The strong acquired systemic humoral 
immune response induced by LtxA indicates direct contact between this molecule and cells of 
lymphoid origin [29,70]. The ability of LtxA to induce apoptosis in lymphocytes might contribute to a 
locally impaired acquired immune response in periodontal infections. The ability of LtxA to affect also 
the lymphocytes indicates a possible role of this molecule in Th1/Th2/Th17 differentiation, a process that 
seems to be of great importance in the pathogenesis of inflammatory diseases, such as periodontitis [69]. 
6.3. Monocytes/Macrophages 
It was early shown that human monocytes are sensitive targets for LtxA, and described that the 
sensitivity of these subsets of leukocytes was at  a similar  level as for human PMNs [51]. 
Characterization of the LtxA induced monocyte killing has described three  different phases:  
(1) cessation of the membrane undulating folding and an accumulation of granulae in the perinuclear 
area;  (2) abnormal membrane movement and strings  of cytoplasm projecting from the cell;  
(3) explosive release of cytoplasmic material from the cell [52]. However, it should be taken into 
consideration that this study was made with a crude LtxA extract that contained a large number of 
other bacterial components. Rabie and co-workers [63,64] showed that purified LtxA caused a rapid 
death of human monocytes in mixtures of the toxin with peripheral blood mononuclear   
leukocytes (MNL). 
More recently, analyses of different subsets of leukocytes separated from peripheral blood of a 
single donor showed that monocytes have an enhanced sensitivity to LtxA compared to PMNs and 
lymphocytes [65]. The LtxA-induced monocyte lysis was shown to involve activation of caspase-1, 
which indicates involvement of proinflammatory intracellular signaling (Figure 6). Caspase-1 is a 
cytosolic cysteine proteinase that specifically induces activation and secretion of the proinflammatory 
cytokines interleukin-1β  (IL-1β) and interleukin-18 (IL-18) [71,72].  Both these proinflammatory 
cytokines are expressed as biologically inactive precursors and have to be cleaved by caspase-1 for 
activation and secretion. Caspase-1 is activated by incorporation in a cytosolic multimer complex 
named the inflammasome [73]. The intracellular  signaling pathways involved in LtxA-induced Toxins 2011, 3             
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inflammasome activation in human monocytes/macrophages have not yet been determined. A partial 
characterization of this process indicates involvements of K
+  efflux and ATP-release that might 
activate purogenic receptors, such as the P2X7
Figure 6.  Schematic illustration of  cellular mechanisms involved in LtxA-induced 
monocyte/macrophage death. It is suggested that LtxA adheres to the target cell membrane 
through binding to the LFA-1 dimer and further anchorage of the molecule by insertion of 
the fatty acid into the membrane lipid bilayer. The hydrophobic domain of the toxin is 
thought to cause small pores in the target cell membrane. Through still undefined 
intracellular signaling pathways, this interaction with the target cell membrane causes 
activation of caspase-1 and IL-1β that are secreted in a bioactive form from the affected cell. 
 [74]. Caspase-1 activation is also caused by several 
other gram-negative pathogens, such as Salmonella and Shigella species, and it has been shown to be 
an important innate immune effector mechanism against intracellular bacteria [75]. 
 
The observation that LtxA induces activation of caspase-1 in human inflammatory defense cells 
indicates a new role of this virulence factor as a mediator of proinflammatory host response. Human 
macrophages (adherent blood monocytes) exposed to LtxA activate a rapid and abundant secretion of 
bioactive IL-1β [76]. Culture supernatants of LtxA exposed macrophages induces bone resorption in 
cultured mouse calvaria and the addition of monoclonal antibodies against IL-1β to the assay abolished 
this activation. This data indicated that bone resorption caused by culture supernatants of LtxA 
exposed macrophages is mainly caused by the activated and released IL-1β [76]. Moreover, exposure 
of human macrophages to components of gram-negative oral pathogens causes an  increased 
accumulation of cytosolic pro-IL-1β  that not is  activated and released [77]. LtxA or  leukotoxic  
A. actinomycetemcomitans induces cleavage and secretion of this accumulated macrophage IL-1β, a 
property that was abolished in A. actinomycetemomitans mutants without LtxA expression. The IL-1β 
secretion was activated already at a concentration of one bacteria/macrophage in interactions with 
bacteria from the highly leukotoxic JP2 clonal type of A. actinomycetemcomitans and with a similar 
activation by low leukotoxic bacteria at a 10-times higher concentration [77]. Taken together, these Toxins 2011, 3             
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data showed that LtxA is the major component of A. actinomycetemcomitans  for induction of 
activation and release of IL-1β from human macrophages and that this effect was further enhanced by 
priming of the macrophages with other bacterial components. 
Macrophages are rare cells in a healthy periodontium but are often found in high numbers in tissues 
from periodontal lesions [67]. These cells are recruited to the infected site from the peripheral blood 
monocytes that are attracted by ICAM-1 expressing endothelial cells. The monocytes pass through the 
vessel wall and migrate towards a gradient of compounds in the connective tissue that are released 
from the oral biofilm and the activated host cells [78]. During diapedesis, the monocytes differentiate 
into macrophages and the inflammatory machinery is up-regulated during this process and further 
during  the migration towards the infected site. This process involves an accumulation of 
proinflammatory precursor molecules, such as IL-1β and IL-18, in the migrating macrophages [79]. 
A secondary stimulus is needed to induce activation and release of the accumulated precursors   
of IL-1β  and IL-18 in the primed macrophages [72]. In  the case of an infection containing 
A. actinomycetemcomitans, the gradient of bioactive components in the connective tissue will contain 
LtxA, and the migrating macrophages will sooner or later meet concentrations of LtxA that activates 
secretion of these proinflammatory cytokines into the surrounding tissues. If this process is activated in 
the tooth supporting tissues in the  vicinity  to  the infection,  it might cause imbalance in the host 
inflammatory response and promote pathogenic cellular mechanisms. Initial analyses of gingival 
crevicular fluid indicate an association between enhanced IL-1β  levels and high number of 
A. actinomycetemcomitans in the periodontal pocket [77]. 
The highly systemic immunogenic host response against LtxA of A. actinomycetemcomitans infected 
subjects indicates direct contact between the antigen presenting macrophages and LtxA [29,70]. The 
enhanced LtxA-sensitivity of human macrophages indicates that these antigen presenting cells might be 
affected during a primary infection with leukotoxic A. actinomycetemcomitans, which might cause a 
delayed acquired immune response. 
The proinflammatory response associated with degenerative diseases is a focus of research in many 
different medical disciplines [72]. A  variety of safe and effective anti inflammatory agents are 
available today and commonly used to  treat many autoimmune or autoinflammatory disorders, 
neurodegenerative disease, or cancer. Increased knowledge of the cellular and molecular mechanisms 
involved in the pathogenesis of periodontitis might open up possibilities for new specific therapeutic 
agents and strategies in the future. The cellular and molecular targets for specific blockage of the 
inflammatory response to infection, as well as the possible therapeutic agents now and in the future, 
have recently been extensively reviewed [72].  
6.4. Erythrocytes 
The ability of some strains of A. actinomycetemcomitans to cause β-hemolysis on blood agar plates 
has been known for many years [80,81]. It was later determined that hemolysis of red blood cells of 
human and animal origin that is caused by A. actinomycetemcomitans  involve interaction with   
LtxA [54]. Different strains of the bacterium with various expression of LtxA show a specific pattern 
when cultured on blood agar plates containing fresh horse blood. Red blood cells lack expression of the 
LtxA receptor LFA-1, which has been shown to be a prerequisite for LtxA-induced leukocyte lysis [40]. Toxins 2011, 3             
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The cellular and molecular mechanisms for this hemolytic effect of LtxA are therefore not fully 
understood. The ability of LtxA to lyse red blood cells has been described in detail by Kachlany [11] in a 
recently published review. Whether this hemolytic property of LtxA is a virulence mechanism is still 
not known. 
7. Acquired Humoral Immune Response to LtxA 
The specific role of humoral immunity in periodontal disease progression has not been fully 
elucidated, although the induction of antibody response is suggested to be beneficial for the host in the 
fight against periodontal infections [82]. On the other hand, the acquired immune response against 
periodontal pathogens has been shown to mediate disease associated mechanisms, such as bone 
resorption [83,84]. It has clearly been shown that leukotoxin specific antibodies are present in the 
peripheral circulation of both periodontally healthy and diseased subjects [29,70]. Plasma samples 
from the subjects with specific immunoreactivity against LtxA have been shown to neutralize LtxA 
activity and contain  enhanced antibody titers against whole cells of A. actinomycetemcomitans  in 
comparison with samples from subjects without immunoreactivity to LtxA [70].  It has also been 
shown that systemic leukotoxin neutralization is correlated to the presence of this bacterium in the oral 
subgingival biofilm [59,60,85,86]. Systemic LtxA antibodies have been shown to be present in >50% 
of  samples from adults and with a similar prevalence in periodontally healthy and periodontally 
diseased subjects [29,87]. Interestingly, systemic LtxA neutralizing capacity correlates to decreased 
risk of the incidence of stroke in women [88]. The mechanism behind this phenomenon has not yet 
been determined but indicates a role of LtxA in the association seen between peridontitis and   
cardiovascular diseases [6]. 
A general opinion  is that the aquired  humoral immune response against antigens of the oral 
subgingival microbiota is both local and systemic [82]. Whether the LtxA activity can be neutralized in 
the gingival pocket by specific antibodies is not known and there has been no report about the presence 
of LtxA neutralizing antibodies in the gingival crevice fluid. The strong correlation between prevalence 
of highly leukotoxic A. actinomycetemcomitans and the development of attachment loss [16] indicates a 
minor role of neutralizing antibodies in the infected periodontal pocket. However, it can be assumed 
that systemic LtxA neutralizing antibodies are an important protection against the systemic side effects 
that are associated with periodontitis, such as increased risk for diabetes and cardiovascular diseases [6]. 
It could further be speculated that the ability of LtxA to specifically affect the immune cells, in 
particular the antigen presenting monocytes/macrophages, causes a delayed acquired immune response 
in the primary A. actinomycetemcomitans infection. 
8. Conclusions 
The ability of LtxA to cause death of all subsets of cells with hematopoetic origin might contribute 
to help the bacterium to survive the host immune response and also to release compounds essential for 
bacterial growth. The more recent discoveries that LtxA mediates activation and release of proteolytic 
enzymes from PMNs and proinflammatory cytokines from monocytes/macrophages indicate a more 
direct role of LtxA in the pathogenesis of periodontal diseases. Unfortunately there is no animal model 
available for studying the virulence mechanisms of LtxA because of its specificity against defense Toxins 2011, 3             
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cells of human or those of old world monkey origin. However, the strong correlation between the 
presence of highly leukotoxic (JP2-clone) A. actinomycetemcomitans and development of attachment 
loss in adolescents indicates an important role of LtxA in the pathogenesis of aggressive   
periodontitis [3]. The treatment strategies of periodontal disease are today focused on the elimination 
of the bacteria in the subgingval biofilm by mechanical techniques or with antibacterial agents [89]. 
Therapeutic agents that target the cellular and molecular inflammatory host response might be a future 
treatment alternative for periodontal disease.  
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